Minoxidil
FDA-approved product (tablet, oral), marketed as Loniten, Men's Rogaine, Minodyl and 9 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Alopecia
- Androgenetic alopecia
- Hypertension
- Hypotrichosis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Pyrimidine derivatives; Other dermatologicals
- FDA pharmacologic class
- Arteriolar Vasodilator FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae11.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis58.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Minoxidil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DichlorphenamideExisting use: Glaucoma73.9% AI-predicted activityagainst M. tuberculosisLab records exist2 registered studies
- Tamsulosin HydrochlorideExisting use: Benign prostatic hyperplasia, Prostate carcinoma73.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Thiethylperazine MalateExisting use: Allergic disease71.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease71.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more71.3% AI-predicted activityagainst M. tuberculosis26 registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder71.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma71.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more70.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydrochlorothiazideExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 9 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more70.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more69.2% AI-predicted activityagainst M. tuberculosis5 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Minoxidil 2% for Eyebrow Enhancement
NCT01672307 · start 2012-09
Registered record
- Registry ID
- NCT01672307
- Conditions
- Hypotrichosis of Eyebrows; Thinning Eyebrows
- Interventions
- Minoxidil lotion 2%; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2012-09
- Completion
- 2013-03
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypotrichosis of Eyebrows; Thinning EyebrowsInterventionMinoxidil lotion 2%; PlaceboPhasePhase 4Registry statusCompletedMicroarray Analysis of Scalp Biopsies After Minoxidil Treatment
NCT01309191 · start 2011-04
Registered record
- Registry ID
- NCT01309191
- Conditions
- Androgenetic Alopecia
- Interventions
- Minoxidil; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2011-04
- Completion
- 2012-04
- Enrolment
- 14
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAndrogenetic AlopeciaInterventionMinoxidil; PlaceboPhaseNot applicableRegistry statusCompletedA Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512)
NCT01451125 · start 2010-05
Registered record
- Registry ID
- NCT01451125
- Conditions
- Androgenetic Alopecia; Male Pattern Baldness; Female Pattern Baldness
- Interventions
- Autologous cultured dermal and epidermal cells
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2010-05
- Completion
- Not recorded
- Enrolment
- 43
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAndrogenetic Alopecia; Male Pattern Baldness; Female Pattern BaldnessInterventionAutologous cultured dermal and epidermal cellsPhasePhase 2Registry statusCompletedEfficacy of Minoxidil in Children With Williams-Beuren Syndrome
NCT00876200 · start 2009-03
Registered record
- Registry ID
- NCT00876200
- Conditions
- Williams Beuren Syndrome
- Interventions
- Minoxidil; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-03
- Completion
- 2015-08
- Enrolment
- 21
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionWilliams Beuren SyndromeInterventionMinoxidil; PlaceboPhasePhase 2Registry statusCompletedEfficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss
NCT00175617 · start 2005-09
Registered record
- Registry ID
- NCT00175617
- Conditions
- Female Pattern Hair Loss
- Interventions
- Spironolactone; Minoxidil
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-09
- Completion
- 2009-03-09
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFemale Pattern Hair LossInterventionSpironolactone; MinoxidilPhasePhase 2Registry statusCompleted